Qyuns Therapeutics Co (HKSE:02509) Other Current Receivables: HK$51 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02509 Qyuns Therapeutics Co Ltd HKSE:02509
9 GF Score
Price HK$16.24
! 6 Warning Signs
View Full Analysis

What is Qyuns Therapeutics Co Other Current Receivables?

Qyuns Therapeutics Co HKSE:02509 -1.10% 9 Other Current Receivables is HK$51 Mil as of Jun. 2026. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 6 warning signs investors should review.

Qyuns Therapeutics Co's Other Current Receivables for the quarter that ended in Jun. 2026 was HK$51 Mil.

Qyuns Therapeutics Co's quarterly Other Current Receivables declined from Jun. 2025 (HK$1.06 Mil) to Dec. 2025 (HK$0.20 Mil) but then increased from Dec. 2025 (HK$0.20 Mil) to Jun. 2026 (HK$51.07 Mil).

Qyuns Therapeutics Co's annual Other Current Receivables increased from Dec. 2023 (HK$0.40 Mil) to Dec. 2024 (HK$0.64 Mil) but then declined from Dec. 2024 (HK$0.64 Mil) to Dec. 2025 (HK$0.20 Mil).

Qyuns Therapeutics Co Other Current Receivables Related Terms

Qyuns Therapeutics Co Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Qyuns Therapeutics Co's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qyuns Therapeutics Co Other Current Receivables Chart

Qyuns Therapeutics Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
0.43 0.74 0.40 0.64 0.20

Qyuns Therapeutics Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only 1.65 0.64 1.06 0.20 51.07
HKSE:02509
9GF Score
Qyuns Therapeutics Co Ltd HKSE:02509
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qyuns Therapeutics Co Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of HK$51 Mil mean?
Qyuns Therapeutics Co (HKSE:02509) has a Other Current Receivables of HK$51 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Qyuns Therapeutics Co and its competitors.
Is Qyuns Therapeutics Co's Other Current Receivables too high?
Qyuns Therapeutics Co's current Other Current Receivables is HK$51 Mil. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Other Current Receivables compare to VRTX and REGN?
Qyuns Therapeutics Co's Other Current Receivables of HK$51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Qyuns Therapeutics Co and its competitors. Qyuns Therapeutics Co's current Other Current Receivables is HK$51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Other Current Receivables of HK$51 Mil. The current Other Current Receivables is HK$51 Mil. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Other Current Receivables is HK$51 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Qyuns Therapeutics Co Business Description

Address No. 907 Yaocheng Avenue, Room 1310, Building 1, Taizhou, Jiangsu, CHN
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score

Get the complete analysis for HKSE:02509

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$16.24
Price